Palisade Bio Inc (PALI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Palisade Bio Inc (PALI) has a cash flow conversion efficiency ratio of -0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.89 Million) by net assets ($127.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Palisade Bio Inc (PALI) net asset quality to measure how much of total assets are equity-financed.
Palisade Bio Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Palisade Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Palisade Bio Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Palisade Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palisade Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing SunwayWorld Science & Technology Co. Ltd.
SHE:301159
|
N/A |
|
Zoneco Group Co Ltd
SHE:002069
|
0.203x |
|
Antibiotice Ia
RO:ATB
|
-0.042x |
|
Guangzhou Seagull Kitchen And Bath Products Co Ltd
SHE:002084
|
0.042x |
|
Selvaag Bolig ASA
OL:SBO
|
0.106x |
|
Svedbergs i Dalstorp AB (publ)
ST:SVED-B
|
-0.028x |
|
Vetropack Holding SA
SW:VETN
|
0.157x |
|
GENERALFINANCE SPA
F:VG30
|
-0.212x |
Annual Cash Flow Conversion Efficiency for Palisade Bio Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Palisade Bio Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Palisade Bio Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $129.38 Million | $-10.85 Million | -0.084x | +94.85% |
| 2024-12-31 | $7.49 Million | $-12.19 Million | -1.627x | -65.38% |
| 2023-12-31 | $11.31 Million | $-11.13 Million | -0.984x | +8.08% |
| 2022-12-31 | $12.48 Million | $-13.36 Million | -1.071x | +46.63% |
| 2021-12-31 | $7.37 Million | $-14.77 Million | -2.006x | -398.65% |
| 2020-12-31 | $-7.10 Million | $-4.77 Million | 0.672x | +147.45% |
| 2019-12-31 | $5.13 Million | $-7.26 Million | -1.415x | -11.32% |
| 2018-12-31 | $6.05 Million | $-7.69 Million | -1.272x | +19.29% |
| 2017-12-31 | $8.52 Million | $-13.42 Million | -1.576x | -14.32% |
| 2016-12-31 | $11.33 Million | $-15.62 Million | -1.378x | +63.84% |
| 2015-12-31 | $4.97 Million | $-18.93 Million | -3.811x | -476.88% |
| 2014-12-31 | $17.72 Million | $-11.71 Million | -0.661x | +47.49% |
| 2013-12-31 | $8.42 Million | $-10.59 Million | -1.258x | -3.48% |
| 2012-12-31 | $6.97 Million | $-8.48 Million | -1.216x | +75.08% |
| 2011-12-31 | $1.66 Million | $-8.10 Million | -4.878x | -283.86% |
| 2010-12-31 | $7.85 Million | $-9.98 Million | -1.271x | -223.88% |
| 2009-12-31 | $-5.02 Million | $-5.14 Million | 1.026x | +162.85% |
| 2008-12-31 | $4.20 Million | $-6.86 Million | -1.632x | -177.74% |
| 2007-12-31 | $6.81 Million | $-4.00 Million | -0.588x | +72.65% |
| 2006-12-31 | $1.55 Million | $-3.33 Million | -2.148x | -235.69% |
| 2005-12-31 | $-460.17K | $-728.59K | 1.583x | -- |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibroste… Read more